Prostate-specific antigen testing in men aged 40-64 years: Impact of publication of clinical trials

James S. Goodwin, Alai Tan, Elizabeth Jaramillo, Yong Fang Kuo

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


We assessed the impact of the publication of trials and changes in recommendations on the rates of prostate-specific antigen (PSA) screening in men aged 40 to 64 years by analyzing monthly medical claims for PSA testing in a commercial insurance database from 2001 to 2011, covering more than 1.5 million men in each year. The testing rates for men aged 40 to 49 years, 50 to 59 years, and 60 to 64 years were 12.1%, 32.7%, and 42.7%, respectively, in 2001 vs 15.7%, 34.2%, and 42.0%, respectively, in 2011. Men aged 40 to 49 years experienced a gradual increase in testing rate from 2001 through 2008 (annual change in PSA testing per 10 000 men [AC] = 4.37; P <. 001), which became flat from mid-2009 through 2011(AC = -0.06; P =.98). The slope of PSA testing rates did not change in men aged 50 to 59 years or 60 to 64 years with the publication of the results of the large trials in 2009 or with the subsequent changes in recommendations on PSA testing.

Original languageEnglish (US)
Pages (from-to)743-745
Number of pages3
JournalJournal of the National Cancer Institute
Issue number10
StatePublished - May 15 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prostate-specific antigen testing in men aged 40-64 years: Impact of publication of clinical trials'. Together they form a unique fingerprint.

Cite this